Premium
Effects of fibrates on duodenal contractions
Author(s) -
Peuler Jacob D.,
Belisle Danica,
Phelps Laura E.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1157.3
Subject(s) - gemfibrozil , bezafibrate , duodenum , endocrinology , in vivo , medicine , chemistry , motility , pharmacology , biology , cholesterol , genetics , microbiology and biotechnology
Fibrates (e.g. gemfibrozil) are a class of lipid‐lowering drugs that have been used clinically for over 80 years. But fibrates cause adverse gastrointestinal (GI) side effects, which occur with them all but more frequently with gemfibrozil. Our recent work showed that gemfibrozil could inhibit spontaneous contractility of intact duodenal tissues isolated from female rats. If this occurs in vivo in the form of decreased motility, it would help explain such side effects. In the present work, we found that gemfibrozil can also inhibit spontaneous contractions in duodenum from male rats. Secondly, we found that bezafibrate and fenofibrate can also inhibit spontaneous duodenal contractions but gemfibrozil does so to a greater extent. Thirdly, we found that pretreatment with tetrodotoxin did not affect gemfibrozil's ability to inhibit such contractions. Thus, that ability is not due to an action of gemfibrozil on enteric neuronal activity. Finally, we found that contractions induced by acetylcholine and 5‐hydroxytryptamine can be inhibited by gemfibrozil. Thus, gemfibrozil appears to nonspecifically inhibit duodenal smooth muscle contractions induced by at least two known intestinal contractile substances, an action which if present in vivo may help explain its GI side effects and likely those of other fibrates. Support: MWU Masters Program.